Dataset Information

An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

ABSTRACT: Aging western societies are facing an increasing prevalence of chronic inflammatory and degenerative diseases for which often no effective treatments exist, resulting in increasing health-care expenditure. Despite high investments in drug development, the number of promising new drug candidates decreases. We propose that preclinical research in non-human primates can help to bridge the gap between drug discovery and drug prescription. Translational research covers various stages of drug development of which preclinical efficacy tests in valid animal models is usually the last stage. Preclinical research in non-human primates may be essential in the evaluation of new drugs or therapies when a relevant rodent model is not available. Non-human primate models for life-threatening or severely debilitating diseases in humans are available at the Biomedical Primate Research Centre (BPRC). These have been instrumental in translational research for several decades. In order to stimulate European health research and innovation from bench to bedside, the European Commission has invested heavily in access to non-human primate research for more than 20?years. BPRC has hosted European users in a series of transnational access programs covering a wide range of research areas with the common theme being immune-mediated inflammatory disorders. We present an overview of the results and give an account of the studies performed as part of European Union Framework Programme (EU FP)-funded translational non-human primate research performed at the BPRC. These data illustrate the value of translational non-human primate research for the development of new therapies and emphasize the importance of EU FP funding in drug development.

SUBMITTER: Haanstra KG

PROVIDER: S-EPMC5098224 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

Haanstra Krista G KG Jonker Margreet M 't Hart Bert A BA

Frontiers in immunology 20161107

Aging western societies are facing an increasing prevalence of chronic inflammatory and degenerative diseases for which often no effective treatments exist, resulting in increasing health-care expenditure. Despite high investments in drug development, the number of promising new drug candidates decreases. We propose that preclinical research in non-human primates can help to bridge the gap between drug discovery and drug prescription. Translational research covers various stages of drug developm ...[more]

PMID: 27872622

Similar Datasets

Project description:In the framework of the collaborative environmental governance and specifically of network concepts, this study makes an exploratory analysis of the EU-funded LIFE sub-programme for the Environment (LIFE-ENV) and its priority area Environment and Resource Efficiency focused on the role of networks and in particular of intermediary organizations by using Social Network Analysis (SNA). More specifically, by investigating the evolving pattern of key statistics (density, clustering coefficient, betweenness and degree centrality) related to bipartite (organisations and projects) and dynamic (eleven years) networks, we identified 3003 organisations and 1006 projects and studied how they operate by forming new relations and reorganising existing connections. Results evidence that the LIFE-ENV attests a structural coherence and a stable structure over time and it is characterised by four different structures of network components, namely isolated coordinating beneficiary, isolated components, small components and giant components. Moreover, the LIFE-ENV is not a cohesive network, due to low values of both density and clustering coefficient. Based on betweenness centrality and degree centrality measures, the LIFE-ENV sub-programme has facilitated the emergence of 4855 intermediary organisations, which equals 29.5% of the total number of coordinating and associate beneficiaries involved in the programme in the eleven years considered. Transnational cooperation in the LIFE-ENV sub-programme is characterised by a different intensity of relations: some countries (i.e. Italy, Spain and Belgium) implement transnational cooperation with multiple European countries in both the North and South of Europe, while others tend to cluster with countries in the same geographical area, and lastly East European countries have limited participation in transnational cooperation. Our analysis supports the hypothesis of a declining collective action in the LIFE-ENV sub-programme.

Dataset Information

An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

Publications

An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets